ProSight Israeli Company

ProSight (www.prosight.site) developed a novel modality in prostate cancer. Our invention - based on knowhow from the Weizmann Institute of Science - allows workflow-neutral real-time use of the hallmark biomarker of prostate cancer in the clinical flow. ProSight has the promise of a leap in prostate cancer, becoming standard of care, present in every clinic and hospital. ProSight brings certainty, the lack of which is th#1 hindering factor in practicing focal therapy and allowing tailored treatment - with all the positive implications on patients and the health systems.